Skip to content
Review Open access

Cannabinoid therapeutics in the 21st century: from molecular mechanisms to equitable clinical integration

Aug 2026 · Exploration of Drug Science · 0 citations · 156 references

TL;DR

This study provides a comprehensive synthesis of the current state of knowledge on cannabinoid research in the 21st century, using evidence from Scopus, PubMed, and Google Scholar using Medical Subject Headings-based search strategies.

Abstract

Cannabis sativa has a long history in ethnomedicine, but advances in molecular biology and regulatory shifts have reignited global interest in its therapeutic potential. Cannabinoid research in the 21st century spans molecular pharmacology, clinical applications, and public health integration. This study provides a comprehensive synthesis of the current state of knowledge. This narrative review synthesizes evidence from Scopus, PubMed, and Google Scholar using Medical Subject Headings-based search strategies. Only articles published in English were included, without restrictions on publication year; however, greater emphasis was placed on recent studies to ensure currency, while seminal and historically important publications were included where necessary to provide foundational context. Relevant studies were thematically analyzed and summarized under predefined headings. Major phytocannabinoids have been identified, with Δ9-tetrahydrocannabinol, cannabidiol, and cannabigerol as key therapeutic candidates. Preclinical studies have shown neuroprotective, anti-inflammatory, analgesic, immunomodulatory, and anticancer effects, but clinical translation remains limited by variability, dosing challenges, and inconsistent reproducibility. These effects are mediated through the endocannabinoid system and related receptor networks. Emerging evidence suggests that epigenetic regulation and precision medicine approaches may enhance individualized cannabinoid therapy. However, safety concerns, including cognitive and psychiatric effects, drug interactions, and dependence, require robust pharmacovigilance. Fragmented regulatory frameworks continue to hinder research and equitable access, underscoring the need for standardized formulations, clinician training, and equity-focused integration into health systems. Cannabinoid therapeutics represent a rapidly evolving field with promise in multiple medical domains. Future progress hinges on harmonizing regulations, expanding clinical evidence, and integrating precision medicine, equity, and public health principles to maximize therapeutic benefits while minimizing risks.

Read PDF

Similar papers

Open access Oct 2026

From Biological Activity to Precision Cannabinoid Oncology

Cannabinoids have gained increasing attention as potential anticancer agents because of their ability to modulate diverse cancer-associated signaling pathways and biological processes.: Cannabinoids, including cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), can influence tumor proliferation, apoptosis, angiogenesi...

W. Lee, S. Go · 0 citations
Review Sep 2026

Global Regulatory Frameworks for Cannabinoids and Cannabis-Based Medicinal Products: A Comprehensive Review of Contemporary Approaches and Challenges.

A greater international regulatory harmonization, stronger quality assurance frameworks, and evidence-based monitoring systems are required for cannabinoids and cannabis products, crucial for protecting public health, supporting scientific research, and enabling the responsible integration of cannabinoid-based therapie...

Shalini Dwivedi, J. G. Vargas, S. Lal · 0 citations
Open access Sep 2026

Cannabinoids in Diabetes: Integrating Scientometric Trends with Mechanistic, Pharmacokinetic, and Clinical Evidence

Cannabinoid signaling has attracted increasing interest in diabetes because the endocannabinoid system regulates energy balance, glucose and lipid metabolism, inflammation, and tissue homeostasis. However, its therapeutic relevance remains uncertain. This study combined scientometric mapping with a critical synthesis o...

Isabella de Fátima Ramos de Almeida, Andressa Zago, Ariane Krause Padilha Lorenzett et al. · 0 citations
Review Open access Sep 2026

The Endocannabinoid System is No Longer the Limiting Factor: Why Policy and Stigma Continue to Delay Cannabinoid-Based Medicine.

This commentary critically synthesizes historical, regulatory, and contemporary evidence on cannabinoid research, integrating data from regulatory documents, international policy reports, clinical and observational studies, systematic reviews, and qualitative investigations to examine whether the persistent gap between...

J. D. de Souza, P. Martins-Filho, J. de Souza Siqueira Quintans et al. · 0 citations
Review Open access Sep 2026

Cannabis and Cannabinoids in Cancer Treatment: A Critical Narrative Review of Supportive Care, Antitumour Evidence, Safety and Translational Gaps

Cannabis and cannabinoid-based products are increasingly used by people with cancer, yet the term “cancer treatment” encompasses two fundamentally different questions: whether cannabinoids can relieve cancer- or treatment-related symptoms, and whether they can modify tumour biology sufficiently to function as anticance...

B. G. Ibokette, Uyoyou Winners Efi, Efe Oni et al. · 0 citations
Review Open access Aug 2026

Synthetic Cannabinoids: A Bibliometric Analysis

Aim: Synthetic cannabinoids (SC) are one of the fastest-spreading and most concerning classes of new psychoactive substances. Originally synthesized for scientific research, these compounds have rapidly begun to be abused due to their potent psychoactive effects. Compared to Δ9-tetrahydrocannabinol (THC), most SC act a...

Murat Kamalak, Abuzer Gülderen, M. Parlak · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.